New Antiarrhythmic Drugs: Treatment Based on “Mechanism”
In the last 5 years, numerous antiarrhythmic drugs have become available in the United States for investigational use in adults; some of these are being used for the first time in children. Most drugs have numerous cellular electrophysiologic properties, and it is usually not possible, in an individual patient, to determine exactly which property has led to suppression of an arrhythmia. Recently, however, with advances in both clinical and cellular electrophysiology, it has become possible to treat certain arrhythmias with drugs based on their possible “mechanism.” Three of these drugs currently being investigated in children are propafenone, ethmozine, and amiodarone.
KeywordsAntiarrhythmic Drug Ventricular Septal Defect Action Potential Duration Atrial Flutter Right Bundle Branch Block
Unable to display preview. Download preview PDF.
- 2.Garson A, Smith RT, Moak JP: Control of postoperative junctional ectopic tachycardia with propafenone. J Am Coll Cardiol (in press).Google Scholar
- 4.Garson A, Evans V, Smith RT, Moak J, McVey P, McNamara DG: Ethmozine: a promising drug for “automatic” atrial ectopic tachycardia. Proc Cardiovasc Pharm Internl Symp 1985 (in press).Google Scholar
- 5.Garson A (for the Pediatric Electrophysiology Society): Atrial flutter in the young: a collaborative study of 380 cases. Pediatr Cardiol 4: 307, 1983.Google Scholar